carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - karmustin - hodgkin disease; lymphoma, non-hodgkin - antineoplastická činidla - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).
bendamustine kabi 2,5mg/ml prášek pro koncentrát pro infuzní roztok
fresenius kabi s.r.o., praha array - 3463 bendamustin-hydrochlorid - prášek pro koncentrát pro infuzní roztok - 2,5mg/ml - bendamustin
bendamustine accord 25mg/ml koncentrát pro infuzní roztok
accord healthcare polska sp. z o.o., varšava array - 20883 monohydrÁt bendamustin-hydrochloridu - koncentrát pro infuzní roztok - 25mg/ml - bendamustin
bendamustine accord 2,5mg/ml prášek pro koncentrát pro infuzní roztok
accord healthcare polska sp. z o.o., varšava array - 20883 monohydrÁt bendamustin-hydrochloridu - prášek pro koncentrát pro infuzní roztok - 2,5mg/ml - bendamustin
carmustine accord 100mg prášek a rozpouštědlo pro koncentrát pro infuzní roztok
accord healthcare polska sp. z o.o., varšava array - 1989 karmustin - prášek a rozpouštědlo pro koncentrát pro infuzní roztok - 100mg - karmustin
carmustine waymade 100mg prášek a rozpouštědlo pro koncentrát pro infuzní roztok
waymade b.v., amsterdam array - 1989 karmustin - prášek a rozpouštědlo pro koncentrát pro infuzní roztok - 100mg - karmustin
carmustine zentiva 100mg prášek a rozpouštědlo pro infuzní roztok
zentiva, k.s., praha array - 1989 karmustin - prášek a rozpouštědlo pro infuzní roztok - 100mg - karmustin
polivy
roche registration gmbh - polatuzumab vedotin - lymfom b-buněk - antineoplastická činidla - polivy v kombinaci s bendamustin a rituximab je indikován pro léčbu dospělých pacientů s relabující/refrakterní difuzní velkobuněčný b-lymfom (dlbcl), kteří nejsou kandidáty pro transplantaci hematopoetických kmenových buněk. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).
recarbrio
merck sharp & dohme b.v. - imipenem monohydrát, cilastatin sodný, monohydrát relebactam - gram-negativní bakteriální infekce - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 a 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4, a 5. pozornost by měla být věnována oficiálním doporučením pro správné používání antibakteriálních látek.
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.